Biotech Values

[iwfal]

Amphastar delays launching until the earlier of 2014 or FDA approval of a third generic; and ii) Amphastar pays MNTA a 20% royalty on sales.

1) Should that be ammended to "Amphastar delays launching until the earlier of 2014 or FDA approval launch of a third generic; and ii) Amphastar pays MNTA a 20% royalty on sales.

2) What do you think would be the split on the 20% royalty between Sandoz and Momenta?